FindTrial
Sign In

CS-1036 phase 2 study - dose response study of CS-1036 in patients with type 2 diabetes -

CS-1036 phase 2 study - dose response study of CS-1036 in patients with type 2 diabetes -

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221087
Enrollment
Unknown
Registered
2010-05-11
Start date
2010-05-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Type 2 Diabetes

Interventions

investigational material(s) Generic name etc : CS-1036 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: - Patient with type 1 diabetes mellitus - Patient with clinically significant diabetic complications

Design outcomes

Primary

MeasureTime frame
Postprandial glucose—

Secondary

MeasureTime frame
1. plasma glucose, serum insulin, glycoalbumin, 1,5-anhydroglucitol, HbA1c, and urinary C-peptide 2. Safety and tolerability—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026